Protagonist Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
PTGX$135.90+2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · June 30, · · December 31, | ||||||
| | 2024 | 2023 | ||||
| Assets | | | | | | |
| Current assets: | | | | | | |
| Cash and cash equivalents | | $355,643 | | $186,727 | ||
| Marketable securities | | | 208,354 | | | 154,890 |
| Receivable from collaboration partner | | | 43 | | | 10,000 |
| Prepaid expenses and other current assets | | | 6,885 | | | 3,960 |
| Total current assets | | | 570,925 | | | 355,577 |
| Marketable securities - noncurrent | | | 31,447 | | | — |
| Property and equipment, net | | | 1,780 | | | 1,195 |
| Restricted cash - noncurrent | | | 225 | | | 225 |
| Operating lease right-of-use asset | | | 10,252 | | | 954 |
| Total assets | | $614,629 | | $357,951 | ||
| Liabilities and Stockholders’ Equity | | | | | | |
| Current liabilities: | | | | | | |
| Accounts payable | | $3,629 | | $772 | ||
| Payable to collaboration partner | | | — | | | 3 |
| Accrued expenses and other payables | | | 15,175 | | | 19,358 |
| Deferred revenue - current | | | 20,124 | | | — |
| Income taxes payable | | | 2,650 | | | — |
| Operating lease liability - current | | | — | | | 1,141 |
| Total current liabilities | | | 41,578 | | | 21,274 |
| Deferred revenue - noncurrent | | | 20,756 | | | — |
| Operating lease liability - noncurrent | | | 10,971 | | | — |
| Total liabilities | | | 73,305 | | | 21,274 |
| Commitments and contingencies | | | | | | |
| Stockholders’ equity: | | | | | | |
| Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding | | | — | | | — |
| Common stock, $0.00001 par value, 180,000,000 and 90,000,000 shares authorized as of June 30, 2024 and December 31, 2023, respectively; 58,762,063 and 57,708,613 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively | | | 1 | | | 1 |
| Additional paid-in capital | | | 980,558 | | | 952,491 |
| Accumulated other comprehensive loss | | | (249) | | | (105) |
| Accumulated deficit | | | (438,986) | | | (615,710) |
| Total stockholders’ equity | | | 541,324 | | | 336,677 |
| Total liabilities and stockholders’ equity | | $614,629 | | $357,951 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.